IGF2BP1 and thyroid cancer: Exclusive expression of IGF2BP1 and MAGEA3 in ATC was initially validated by Western blotting in two ATC-derived cell lines (C643 and 8305C) and the individual samples of each thyroid cancer subtype comprised in the test cohort (Fig. 2a, b).